Basic Indomethacin Information

• INN (International Nonproprietary Name): Indometacin (also known as Indomethacin in USAN; spelled identically in most major EU languages: Indometacina, Indomethacinum, Indometacinum).
• Brand Names Available In United Kingdom: Indocid; Indometacin generics (commonly supplied as 25 mg and 50 mg capsules).
• ATC Code: M01AB01 (systemic, acetic acid derivatives and related substances); M02AA23 (topical analgesics); S01BC01 (ophthalmological anti‑inflammatory non‑steroids); C01EB03 (closure of ductus arteriosus).
• Forms & Dosages: Oral 25 mg and 50 mg capsules/tablets; rectal 100 mg suppositories; topical 4% gel; IV indomethacin sodium (0.2 mg/mL) used for neonatal patent ductus arteriosus in specialist settings; sustained‑release 75 mg capsules in select markets.
• Manufacturers In United Kingdom: Branded supply includes Indocid and a range of generic manufacturers supplied to the UK market; European suppliers such as Sandoz, Zentiva and Mylan are common wholesalers for UK pharmacies.
• Registration Status In United Kingdom: Registered and regulated with MHRA; product listings correspond to EMA/MHRA approvals and to international regulatory registrations.
• OTC / Rx Classification: Prescription Only (Rx) in the United Kingdom and in other major markets due to the safety profile and potential for serious adverse effects.

Key Findings From Recent Trials

Major 2022–2025 Studies

Which recent trial results matter to prescribers and parents of newborns?

Large neonatal cohorts and multicentre reviews since 2022 continue to support intravenous indometacin for closure of patent ductus arteriosus where COX inhibition is required.

Randomised trials in adults and pragmatic clinical studies have concentrated on topical formulations and short oral courses for acute indications such as gout and headache.

Several meta‑analyses compared indometacin with ibuprofen for neonatal PDA closure and found comparable efficacy in many settings.

Main Outcomes

Neonatal studies reaffirmed that IV indomethacin at neonatal protocols of around 0.2 mg/kg per dose produces clinically meaningful rates of ductal closure.

Adult trials of short systemic courses for acute gout or migraine found faster symptom resolution versus placebo in small randomised controlled trials.

Topical 4% gel produced measurable local pain relief for superficial musculoskeletal complaints while limiting systemic exposure.

Safety Observations

Renal monitoring was repeatedly emphasised for neonates and adults, with transient falls in urine output reported in neonatal series requiring close nursing observation.

For adults, trials showed expected gastrointestinal and cardiovascular concerns with systemic NSAID exposure, reinforcing guidance to use the lowest effective systemic dose.

Post‑marketing pharmacoepidemiology continued to favour topical choices where appropriate to reduce systemic adverse events.

Clinical Mechanism Of Action

Layman’s Explanation

What does indometacin do and why would a clinician choose it?

Indometacin is a non‑steroidal anti‑inflammatory drug that reduces pain, inflammation and fever by blocking the chemical messengers—prostaglandins—that produce these symptoms.

That effect helps in short acute attacks, inflammatory arthritis and, in newborns, it reduces the prostaglandin signal that keeps the ductus arteriosus open.

Scientific Breakdown

Indometacin is an indoleacetic acid NSAID (ATC M01AB01) that inhibits cyclooxygenase enzymes COX‑1 and COX‑2 and so lowers prostaglandin synthesis.

In patent ductus arteriosus, decreasing prostaglandin E2 causes the duct to constrict and often close following the neonatal dosing protocol.

Oral 25 mg and 50 mg capsules give reliable absorption for systemic therapy.

Rectal 100 mg suppositories offer an alternative when oral administration is unsuitable.

Intravenous indomethacin sodium (0.2 mg/mL) allows precise neonatal dosing for PDA closure within specialist neonatal units.

Because COX‑1 inhibition reduces gastric mucosal protection and platelet function, gastrointestinal and bleeding risks are linked to the mechanism.

Renal prostaglandin suppression explains the nephrotoxicity risk, especially in the elderly, dehydrated patients or those on diuretics and ACE inhibitors.

These pharmacodynamic facts guide contraindications such as active peptic ulcer, severe renal impairment and third‑trimester pregnancy.

Scope Of Approved And Off‑Label Use

United Kingdom Approvals

Which conditions is indometacin routinely licensed for in the UK?

Licence indications include inflammatory conditions such as osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and acute gout and certain headaches when clinically indicated.

Available formulations for UK prescribers include 25 mg and 50 mg oral capsules and topical 4% gel; suppositories and IV are available in other jurisdictions and hospital formularies.

Intravenous indomethacin sodium is used in neonatal practice for PDA closure under neonatal unit protocols.

Notable Off‑Label Trends

Clinicians in the UK sometimes use single 25–50 mg doses off‑label to abort migraine or cluster headaches.

Short courses for acute gout (initial 50 mg TDS then taper) remain a common pragmatic choice where rapid pain relief is required and contraindications are absent.

Topical indometacin gel is increasingly used off‑label to limit systemic exposure for local musculoskeletal pain, particularly in patients at higher GI or renal risk.

Dosage Strategy

General Dosing

What is a safe starting approach for adults?

Adults commonly start on 25 mg to 50 mg two to three times daily, aiming for the lowest effective dose and a commonly cited maximum near 200 mg per day.

Sustained‑release 75 mg capsules exist in some markets but should be used cautiously in frail or elderly patients because prolonged exposure increases adverse event risk.

Condition‑Specific Dosing

Osteoarthritis or rheumatoid arthritis is typically managed with 25 mg two to three times daily, adjusted to clinical response.

Acute gout flares often begin with 50 mg three times daily until pain reduces, then taper over several days.

Ankylosing spondylitis dosing ranges from 25–50 mg two to three times daily depending on severity and tolerability.

Neonatal PDA dosing uses IV indomethacin sodium at approximately 0.2 mg/kg per dose according to neonatal unit protocol and cardiology guidance.

Rectal 100 mg suppositories are useful where oral route is unavailable; check local product information for specific administration instructions.

Dose modification is advised for the elderly (for example 25 mg twice daily) and in renal or hepatic impairment where the drug is used only with extreme caution and monitoring.

Safety Protocols

Contraindications

Who should not take indometacin?

Absolute contraindications include hypersensitivity to indometacin or other NSAIDs, active peptic ulceration or gastrointestinal bleeding and inflammatory bowel disease.

Severe hepatic, renal or cardiac failure and a history of NSAID‑induced asthma, urticaria or anaphylaxis are absolute contraindications.

Pregnancy in the third trimester is contraindicated because NSAIDs can cause fetal and neonatal harm.

Adverse Effects

Common mild adverse effects include dyspepsia, nausea, diarrhoea, headache, dizziness and other mild CNS symptoms.

More serious effects include dose‑related gastrointestinal ulceration or bleeding, fluid retention, raised blood pressure, skin rash, tinnitus and renal impairment.

UK practice recommends baseline renal and liver tests and blood pressure measurement before starting systemic therapy and periodic monitoring during prolonged treatment.

Co‑prescribing a proton pump inhibitor for patients on long‑term indometacin may reduce risk of upper GI complications in higher‑risk patients.

For neonates on IV indometacin, monitor urine output, electrolytes and watch carefully for any signs of intracranial haemorrhage per neonatal guidelines.

Patients should be counselled to stop treatment and seek urgent review if they develop black or tarry stools, severe abdominal pain, sudden breathlessness, skin blisters or jaundice.

Interaction Mapping

Food Interactions

Does food change how indometacin works?

Food has minimal effect on indometacin absorption, but taking oral doses with food or a small snack is commonly advised to reduce gastrointestinal irritation.

Drug Combinations To Avoid

Major interactions include increased bleeding risk with anticoagulants (warfarin and DOACs) and additive GI bleed risk when combined with SSRIs, SNRIs or antiplatelet agents.

ACE inhibitors, angiotensin receptor blockers and diuretics can increase the risk of nephrotoxicity when combined with NSAIDs—the so‑called “triple whammy”.

Indometacin can raise plasma levels of lithium and methotrexate and should be used with caution or avoided where monitoring is difficult.

Concurrent corticosteroid use increases the risk of gastrointestinal ulcers.

Avoid using indometacin with other NSAIDs or COX‑2 inhibitors because of additive toxicity.

In neonates, interactions centre more on renal perfusion and concomitant drugs that affect renal output; careful nursing observation and lab monitoring are essential.

Patient Experience Analysis

Survey Data

What do patients report about indometacin use?

Surveys from rheumatology and pain clinics show that short systemic courses give rapid symptom relief for acute gout and certain headaches.

Patients commonly report dyspepsia, dizziness and headache as reasons to stop oral indometacin.

Long‑term users express concerns about gastrointestinal and renal safety and often prefer alternatives if available.

Forum Trends

Online patient communities frequently highlight the topical 4% gel as well tolerated for local pain, while noting it is less helpful for deep joint inflammation.

Common themes include appreciation for rapid relief in acute attacks and frustration over prescription requirements because indometacin remains Rx‑only in official guidance.

Gaps in patient knowledge include the need for renal monitoring and awareness of pregnancy contraindications; clear counselling and shared decision‑making are therefore important.

Distribution And Pricing Landscape

How easy is it to get indometacin in the UK and what influences price?

Indometacin is manufactured widely by generic producers including Sandoz, Zentiva, Mylan and by branded suppliers such as Indocid.

Generic oral capsules (25 mg and 50 mg) are commonly stocked by community pharmacies in the UK and are modest in unit cost due to competition.

Topical 4% gel has a higher per‑gram price but may lower downstream monitoring costs by reducing systemic exposure.

Suppositories and sustained‑release forms are less frequently stocked in community settings and are typically sourced through wholesalers or hospital pharmacy supply for specific needs.

Neonatal IV indometacin procurement is usually handled by hospital pharmacies and priced variably due to low volumes and specialist supply chains.

NHS prescribing tends to favour cheaper generics for chronic conditions; brand choice and availability follow local formulary decisions.

Alternative Options

Comparison Table

Which drugs are used instead of indometacin?

Common NSAID alternatives include ibuprofen, naproxen, diclofenac, ketoprofen and the COX‑2 selective agent celecoxib.

Ibuprofen is widely available, has a shorter half‑life and fewer CNS adverse effects for many patients.

Naproxen offers longer duration of action and in some analyses a different cardiovascular risk profile.

Diclofenac provides potent analgesia but carries a stronger cardiovascular safety signal in population studies.

Celecoxib is more COX‑2 selective and may lower upper GI risk, though cardiovascular caution remains.

Pros And Cons

Indometacin strengths are its potency for inflammation, its established neonatal IV role for PDA and effectiveness in acute gout or certain headaches.

Downsides include a higher incidence of CNS effects, notable GI and renal risk and contraindication in late pregnancy.

Choice of agent should take into account cardiovascular, gastrointestinal and renal risks, the target tissue (superficial versus deep joint), and whether topical therapy can achieve benefit while lowering systemic exposure.

Regulatory Status

What are the legal and monitoring expectations in the UK?

Indometacin is prescription‑only and is registered with MHRA in the UK in line with EMA and other major regulators.

ATC classifications include M01AB01 for systemic use, M02AA23 for topical products and C01EB03 to indicate its role in ductus arteriosus closure.

Hospital neonatal use of IV indometacin follows specialist protocols and local formulary approval.

Suspected serious adverse reactions should be reported to the Yellow Card scheme as part of UK pharmacovigilance.

Consolidated FAQ

Short Q&A For Clinicians & Patients

Is indometacin available over the counter in the UK?

No. Officially indometacin is prescription‑only in the United Kingdom.

Which formulations are commonly used?

Oral 25 mg and 50 mg capsules, rectal 100 mg suppositories, topical 4% gel and IV indometacin sodium for neonatal PDA; some markets carry SR 75 mg capsules.

What monitoring is required?

Baseline and periodic checks of renal function, liver tests and blood pressure are recommended for systemic use.

Can pregnant patients use indometacin?

It is contraindicated in the third trimester; use in earlier pregnancy requires specialist review and careful risk assessment.

How are missed doses or overdose managed?

A missed dose should be taken when remembered unless it is close to the next dose—do not double up.

In the event of an overdose, urgent hospital admission for symptomatic and supportive care is required.

Visual Guide

Suggested Diagrams And Labelling

Which visual aids help clinicians and patients use indometacin safely?

Suggested diagrams include a dosing flowchart by indication (acute gout, arthritis, neonatal PDA protocol), icons for contraindications and an interaction map showing anticoagulants, ACEi/ARBs/diuretics and psychotropic medicines.

A formulation gallery displaying 25 mg and 50 mg capsules, 100 mg suppositories, 4% gel tubes and IV vials supports correct dispensing and patient counselling.

Clinical Quick‑Reference

Quick cards should state suggested starting doses (for example 25–50 mg PO two to three times daily), a maximum daily limit near 200 mg and a monitoring checklist covering renal function, BP and GI symptoms.

Visual materials should reference MHRA/BNF guidance and include clear patient safety warnings.

Storage And Transport

How should indometacin be stored in a community pharmacy and at home?

Tablets and capsules should be stored below 25°C away from moisture in their original packaging.

Suppositories and topical gels require a cool, dry place and topical gels should not be frozen.

IV indometacin sodium is managed under hospital cold‑chain procedures in accordance with manufacturer instructions.

Packaging commonly includes blister packs of 10–30 tablets, suppository strips of 5–10 and gel tubes of 30–50 g.

Community pharmacy stock should track batch integrity and expiry dates and maintain secure storage.

Delivery Across United Kingdom

Guidelines For Proper Use

Prescribing Checklist

What should clinicians tick off before writing a prescription?

Confirm the indication and prior NSAID tolerance and document shared decision‑making.

Check baseline renal and liver function and record blood pressure before initiation of systemic therapy.

Review all concomitant medicines for anticoagulants, antiplatelets, SSRIs, lithium or methotrexate and assess the need for PPI gastroprotection in long‑term users.

Establish pregnancy status for women of childbearing potential and avoid use in the third trimester.

Choose the most appropriate formulation for the patient—oral 25–50 mg, rectal 100 mg, topical 4% gel or IV in neonatal units.

Patient Counselling Points

What should patients be told at the point of dispensing?

Take oral doses with or after food to reduce dyspepsia and read the patient leaflet for signs of serious adverse effects.

Stop taking the medicine and seek urgent advice for black or tarry stools, severe abdominal pain, sudden breathlessness, facial swelling or a widespread rash.

Advise patients to inform the prescriber if they are taking blood thinners, ACE inhibitors, diuretics, lithium or methotrexate.

For neonates, ensure neonatal unit protocols are followed for IV dosing (typically 0.2 mg/kg) and that urine output and electrolytes are checked regularly.

Report any suspected serious adverse reactions to the Yellow Card scheme.

Note: In our online pharmacy, indomethacin is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.